
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc. has demonstrated a robust market position with increasing Chromium reaction volumes, indicating strong demand for its integrated solutions amid challenges in the pharmaceutical sector. The projected growth of consumables by 5 to 19 times per platform by 2027 highlights the potential for significant revenue expansion, as these consumables are expected to outpace instrument revenue growth. Furthermore, the company's comprehensive product offerings in the life sciences technology market position it favorably to capitalize on ongoing and future investments in biological analysis.
Bears say
10x Genomics has experienced a contraction in 2024, marked by double-digit pricing pressure and flat to modestly lower volumes, with growth anticipated to stagnate until 2027. The company reported weaker than expected Q4 results, missing earnings per share estimates significantly and projecting a full-year revenue outlook that fell short of expectations. Additionally, despite some expansion in business segments since the company's peak stock prices in 2021, the overall performance has not met analyst expectations, contributing to a decline of over 90% in stock value since that peak.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares